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Abstract
Trial Design
This analysis characterizes the degree of early organ involvement in a cohort of oligo-symp-
tomatic untreated young patients with Fabry disease enrolled in an ongoing randomized,
open-label, parallel-group, phase 3B clinical trial.
Methods
Males aged 5–18 years with complete α-galactosidase A deficiency, without symptoms of
major organ damage, were enrolled in a phase 3B trial evaluating two doses of agalsidase
beta. Baseline disease characteristics of 31 eligible patients (median age 12 years) were
studied, including cellular globotriaosylceramide (GL-3) accumulation in skin (n = 31) and
kidney biopsy (n = 6; median age 15 years; range 13–17 years), renal function, and glycolip-
id levels (plasma, urine).
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Results
Plasma and urinary GL-3 levels were abnormal in 25 of 30 and 31 of 31 patients, respective-
ly. Plasma lyso-GL-3 was elevated in all patients. GL-3 accumulation was documented in
superficial skin capillary endothelial cells (23/31 patients) and deep vessel endothelial cells
(23/29 patients). The mean glomerular filtration rate (GFR), measured by plasma disappear-
ance of iohexol, was 118.1 mL/min/1.73 m2 (range 90.4–161.0 mL/min/1.73 m2) and the
median urinary albumin/creatinine ratio was 10 mg/g (range 4.0–27.0 mg/g). On electron mi-
croscopy, renal biopsy revealed GL-3 accumulation in all glomerular cell types (podocytes
and parietal, endothelial, and mesangial cells), as well as in peritubular capillary and non-
capillary endothelial, interstitial, vascular smooth muscle, and distal tubules/collecting duct
cells. Lesions indicative of early Fabry arteriopathy and segmental effacement of podocyte
foot processes were found in all 6 patients.
Conclusions
These data reveal that in this small cohort of children with Fabry disease, histological evi-
dence of GL-3 accumulation, and cellular and vascular injury are present in renal tissues at
very early stages of the disease, and are noted before onset of microalbuminuria and devel-
opment of clinically significant renal events (e.g. reduced GFR). These data give additional
support to the consideration of early initiation of enzyme replacement therapy, potentially
improving long-term outcome.
Trial Registration
ClinicalTrials.gov NCT00701415
Introduction
Fabry disease is a rare, debilitating, X-linked disorder caused by a deficiency of the lysosomal
hydrolase α-galactosidase A (αGAL) leading to the accumulation of globotriaosylceramide
(GL-3) [1]. Accumulation of GL-3 occurs in vascular endothelial and other cell types, leading
to progressive organ damage resulting in a multisystemic disease [2,3]. The kidneys, heart, and
brain are the most vulnerable organs. As the disease progresses, renal, cardiovascular, and cere-
brovascular complications result in morbidity and, for many, early mortality [4–6]. Disease
manifestations in childhood include acroparaesthesia, angiokeratoma, hypohidrosis, tinnitus/
hearing difficulties, gastrointestinal (GI) symptoms, fatigue, and headache [7–9], all of which
have a negative impact on quality of life (QoL).
Impairment of renal function is a prevalent complication that develops in the majority of
men and in a subset of women with untreated Fabry disease [4,10–12]. A spectrum of Fabry
disease-specific kidney lesions (GL-3 accumulation in a variety of renal cell types) and second-
ary pathology related to progression of kidney disease (i.e. glomerular sclerosis, interstitial fi-
brosis) have been observed even in the early clinical stages of Fabry nephropathy [12–16].
Clinical evidence of kidney involvement (e.g. microalbuminuria, proteinuria, reduced glomeru-
lar filtration rate [GFR]) has been reported in children and adolescents [7,9,12,15–18], but de-
tailed characterization of renal disease very early in the natural history of Fabry disease has yet
to be documented. The FIELD (Fabrazyme: Intervening Early at Low Dose) trial is an ongoing
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randomized, open-label, parallel-group, phase 3B study evaluating the long-term efficacy and
safety of enzyme replacement therapy (ERT) with two low-dose treatment regimens of agalsi-
dase beta in treatment-naive male paediatric patients with Fabry disease without clinically sig-
nificant involvement of major organs (i.e. kidney, heart, and brain). The objective of this
manuscript is to systematically report the baseline characteristics of this cohort of 31 treat-
ment-naive male paediatric Fabry patients.
Methods
The protocol for this trial and supporting CONSORT checklist are available as supporting in-
formation; see S1 CONSORT Checklist and S1 Protocol.
Study Design
This is an ongoing randomized, open-label, parallel-group, phase 3B study to evaluate the
long-term efficacy and safety of ERT. All patients and/or their parents/legal guardians provided
written informed consent before any procedures were performed or protocol-specified treat-
ments administered. Patients were randomized to two low-dose treatment regimens of agalsi-
dase beta (Fabrazyme; Genzyme, a Sanofi company, Cambridge, MA, USA): 0.5 mg/kg every 2
weeks; or 1 mg/kg every 4 weeks for 5 years. This ongoing phase 3B study is being conducted
in accordance with Good Clinical Practice as defined by the International Conference on
Harmonization guidelines and the Declaration of Helsinki, and is registered at clinicaltrials.gov
under the identifier NCT00701415. The protocol was approved by the following Institutional
Review Boards and/or Independent Ethics Committees: Medical Ethics Committee AMC, Am-
sterdam, The Netherlands; National Research Ethics Service, Cambridgeshire 4 Research Ethics
Committee, Norwich, United Kingdom; Bioethics Committee, Children's Memorial Health In-
stitute, Warsaw, Poland; University of Bergen, Bergen, Norway; Ethics Committee of the Gen-
eral University Hospital, Prague, Czech Republic; Emory Institution Review Board, Atlanta,
GA, USA; Ethics Committee for Research and Evaluation of Health Technologies, Montreal,
Canada; Cincinnati Children’s Hospital Institutional Review, Cincinnati, OH, USA; Research
Ethics Committee of Children’s Hospital Ricardo Gutierrez, Buenos Aires, Argentina; Teach-
ing and Research Committee of General Children’s Hospital Ricardo Gutierrez, Buenos Aires,
Argentina; Ethics Committee for Research in Humans from the Foundation University of
Passo Fundo, Passo Fundo, Brazil; Western Institutional Review Board, Olympia, WA, USA;
UBC and C&W Research Ethics Board, Vancouver, Canada.
The outcomes following treatment will be reported in a separate publication, once the study
has been completed.
Participants
Males aged between 5 and 18 years with a confirmed diagnosis of Fabry disease were eligible
for inclusion. A diagnosis of Fabry disease was defined as a central laboratory-documented leu-
cocyte αGAL activity of< 4 nmol/hr/mg leucocyte protein. In the absence of the preferred leu-
cocyte assay, patients with documented plasma αGAL activity of< 1.5 nmol/hr/mL were
eligible. Patients were required to have evidence of GL-3 accumulation documented by a plas-
ma GL-3 level> 7.0 μg/mL or a urinary GL-3 level> 0.03 mg/mmol creatinine. Patients with
any of the following characteristics were excluded: micro- or macroalbuminuria (first morning
void urinary albumin/creatinine ratio> 30 mg/g in 2 of 3 consecutive samples, 1 week
apart); GFR, measured by plasma disappearance of iohexol (iGFR),< 90 mL/min/1.73 m2; evi-
dence of stroke or a transient ischaemic attack, or magnetic resonance imaging (MRI) scan
demonstrating white matter hyperintensities> 2 mm in size on T2- or fluid-attenuated
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inversion recovery (FLAIR)-weighted images within the white matter or ganglia; severe and re-
current peripheral pain (i.e. pain episodes occurring more than once a week, with pain that
influenced daily activities regardless of medication, for 3 months); evidence of left-ventricu-
lar hypertrophy (LVH) defined as left-ventricular posterior wall thickness (LVPWT) and/or
inter-ventricular septum thickness (IVST) 2 standard deviations (SDs) compared to normal
based on body surface area normal ranges [19]. Patients who had received prior specific treat-
ment for Fabry disease or who had participated in any other study of an investigational drug
within 30 days of participation in the present study were also excluded.
Assessments
The following baseline assessments of disease were made at the screening visit, before randomi-
zation to treatment.
Plasma and urinary GL-3. Plasma and urine samples were assayed for GL-3 using tandem
mass spectrometry. The upper limit of normal (ULN) was 7.0 μg/mL for the plasma assay [20]
and< 0.030 mg/mmol creatinine for the urine assay. Plasma samples were also analysed for
the isoform lyso-GL-3 (ULN 3 ng/mL).
Accumulation of GL-3 in the skin. GL-3 accumulation was determined from skin biopsy
samples. A 3-mm punch biopsy was taken under local anaesthesia, and masked biopsy speci-
mens, stained as previously described [21], were analysed using light microscopy (LM). Biopsy
specimens were processed immediately after collection, and stored at 4°C in polystyrene vials
containing 15 mL of 3% glutaraldehyde in 0.2 mol/L sodium cacodylate buffer (pH 7.3) until
shipped in glutaraldehyde to the Genzyme Department of Pathology (Framingham, MA,
USA). The level of GL-3 accumulation in skin capillary endothelial cells and, where present,
deep vessel endothelial cells, deep vessel smooth muscle cells, and perineurial cells was scored
as described previously by Thurberg et al. [21]. Scoring was based on a none, mild, moderate,
and severe (0, 1, 2, and 3) scale. A GL-3 score of 0 (none/trace) was considered normal, and
GL-3 scores of 1 (mild), 2 (moderate), and 3 (severe) were considered abnormal [21].
Renal function. GFR was measured using iGFR, based on 6-point sampling including a
pre-injection time point [22]. GFR was also estimated from serum creatinine levels (eGFR)
using age-appropriate formulae (eGFRBedside Schwartz for patients aged< 18 years or eGFRCK-
D-EPI for patients aged 18 years) [23,24]. Median albuminuria and proteinuria values were ob-
tained from 3 consecutive first morning urine voids, taken 1 week apart. Urine beta-
2-microglobulin and retinol binding protein were assayed as biomarkers for renal
tubular damage.
Evaluation of GL-3 and tissue damage in the kidney. Kidney biopsies were obtained
from patients on an optional basis in order to assess the extent of histological renal involve-
ment in this treatment-naive paediatric cohort. The method used for preparation of kidney bi-
opsy samples has been previously reported by Thurberg et al. [25]. LM was used to assess the
level of focal/global glomerulosclerosis.
Quantitative glomerular structural analysis was performed on masked kidney biopsy speci-
mens using electron microscopy (EM). Fractional volume of GL-3 inclusions per cytoplasm of
podocytes (Vv[Inc/PC]), endothelial cells (Vv[Inc/Endo]), and mesangial cells (Vv[Inc/Mes]);
foot process width (evaluating podocyte effacement); and percentage endothelial fenestration
were estimated using systematic, unbiased morphometric sampling, and quantitative methods
as detailed elsewhere [16,26,27]. In addition, GL-3 inclusions in extraglomerular cells were as-
sessed (not quantitatively). All EMmeasurements (with exception of arteriopathy) were done
in uncompromised glomerular structures with intact Bowman’s capsule without obvious me-
chanical distortion (2–3 glomeruli per biopsy).
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Other assessments. Additional assessments included audiology evaluations, listing of GI
symptoms, and assessment of angiokeratoma, if present. Analysis of GLAmutation was per-
formed at screening when the nucleotide sequence of the mutation was not available. QoL was
assessed using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales, Multidi-
mensional Fatigue Scale, and the Paediatric Pain Scale (visual analogue scale). On the pain
scale, a score of 0 indicated no pain or discomfort, and a score of 100 represented severe pain.
Settings and Locations of Data Collection
Data— including audiology assessments, eye examination, echocardiography, and brain MRI
scans— were collected at the 12 study sites. The listing of the study sites is provided in the Ac-
knowledgments section. Analyses of GL-3 (plasma and urine samples), lyso-GL-3 (plasma
samples), GFR, urinary protein, albumin and creatinine levels, as well as all histological assess-
ments (LM for GL-3 scoring of skin biopsies, LM for focal/global glomerulosclerosis, and EM
for kidney biopsy evaluations) were carried out centrally. Echocardiograms, electrocardio-
grams (ECGs) and MRI scans were also analysed centrally. GLA genotyping was carried out
centrally only when not already available at the site.
Statistical Analyses
No formal statistical sample size calculation was performed. The number of patients to be en-
rolled was determined on medical grounds as a compromise between the need to assess safety,
efficacy, and pharmacokinetics in the largest population, and the limitation for recruitment of
this paediatric population in the context of this orphan disease.
Baseline demographics and other patient characteristics were summarized descriptively. Re-
gression analysis was performed to model the linear relationship between age and pain score. A
p value of 0.05 was considered statistically significant.
Results
Patient Demographic Characteristics and Disposition
The study was initiated in May 2008, the first patient enrolled in September 2008 and the last
patient started the study in May 2010; the study is ongoing until May 2015. Of the 44 patients
screened, 10 did not meet the inclusion criteria and 3 withdrew consent prior to receiving treat-
ment (S1 Fig). The primary reasons for screening failures were residual leucocyte or plasma
αGAL activity above the protocol-defined cutoffs (n = 7), plasma or urine GL-3 accumulation
below the protocol-defined cutoffs (n = 4), and echocardiographic evidence of LVH based on
LVPWT and/or IVST 2 SD (n = 2). The two patients with evidence of LVH were brothers,
aged 16 and 18 years at the time of screening. Two patients, one with residual αGAL activity
(aged 18 years) and the 16-year-old boy with LVH, also had iGFR< 90 mL/min/1.73 m2.
Therefore, 31 patients were randomized. The baseline demographics and clinical characteris-
tics are summarized in Table 1. The median age at enrolment was 12.0 years (range 5–18
years).
GLAMutations
The GLAmutations for all patients are presented in Table 2 [28–46]. Genotyping found mis-
sense mutations (n = 19), nonsense mutations (n = 9), and deletions (n = 3).
Early Disease Status in Paediatric Fabry Patients
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Plasma and Urinary GL-3, and Plasma Lyso-GL-3
The plasma GL-3 level was abnormal in 25 of 30 (83%) patients. Mean (SD) plasma GL-3 was
9.9 (2.9) μg/mL with values ranging from 4.6 to 16.8 μg/mL (Table 1). The urinary GL-3 level
was abnormal in all 31 patients. The mean (SD) urinary GL-3 was 600 (400) μg/mmol of creati-
nine with values ranging from 100 to 1,600 μg/mmol (Table 1). Plasma lyso-GL-3 levels were
Table 1. Demographics and clinical characteristics of treatment-naive paediatric patients with non-
severe Fabry disease.a
Parameter Patients (N = 31)
Male sex, n (%) 31 (100)
Median age at Fabry diagnosis (range), years 10 (0–17)
Median age at study enrolment (range), years 12 (5–18)
Patients aged 5–11 years, n (%) 15 (48)
Patients aged 12–18 years, n (%) 16 (52)
White ethnicity, n (%) 29 (94)
Mean heart rate (SD), bpm 75 (16)
Mean systolic blood pressure (SD), mmHg 111 (14)
Mean diastolic blood pressure (SD), mmHg 61 (9)
Family member with Fabry disease, n (%) 30 (97)
αGAL activity, n (%)
Leucocyte αGAL activity < 4.0 nmol/hr/mgb 24 (77)
Plasma αGAL activity < 1.5 nmol/hr/mL 31 (100)
Mean GL-3 (SD)
Plasma, μg/mLc 9.9 (2.9)
Urinary, μg/mmol creatinined 600 (400)
Mean plasma lyso-GL-3 (range), ng/mLe 142.0 (3.1–211.5)
Abnormal hearing, n (%)
Tinnitus 4 (13)
Hearing loss 6 (19)
GI symptoms, n (%)
Abdominal pain 20 (65)
Diarrhoea 10 (32)
Nausea 9 (29)
Vomiting 5 (16)
Angiokeratomas, n (%) 15 (48)
Concomitant medication, n (%)
 1 concomitant medication during the study 19 (61)
Pain medications 14 (45)
Medications to manage GI symptoms 4 (13)
aBaseline demographics and clinical characteristics reported for the overall group. Baseline demographics
and clinical characteristics for each of the treatment groups will be reported once the study has been
completed (in the context of the outcomes of the study).
bLeucocyte information not available for 7 patients.
cNormal plasma GL-3:  7.0 μg/mL.
dNormal urinary GL-3: 1–30 μg/mmol creatinine.
eNormal plasma lyso-GL-3:  3 ng/mL.
αGAL = α-galactosidase A; bpm = beats per minute; GI = gastrointestinal; GL-3 = globotriaosylceramide;
SD = standard deviation.
doi:10.1371/journal.pone.0124987.t001
Early Disease Status in Paediatric Fabry Patients
PLOS ONE | DOI:10.1371/journal.pone.0124987 May 8, 2015 6 / 19
elevated in all 31 patients, ranging from 3.1 to 211.5 ng/mL, with a mean of 142.0 ng/mL and
median of 151.4 ng/mL. The patient with the lowest level had fulfilled all inclusion criteria and
had a p.Asn215Ser mutation, which has been reported to be associated with the cardiac variant
of Fabry disease [32]. Of note, this patient had GI symptoms and a family history of
renal disease.
GL-3 Accumulation in Skin Vascular Endothelium
The GL-3 accumulation level in superficial skin capillary endothelial cells was scored as abnor-
mal (> 0 scores) in 23 of 31 (74%) patients. All 23 patients with abnormal GL-3 scores had ei-
ther mild or moderate accumulation (score of 1 or 2); none of the patients had evidence of
severe GL-3 accumulation (Fig 1). Similarly, 23 of 29 (79%) patients who had data for GL-3 in
deep vessel endothelial cells had mild or moderately abnormal GL-3 accumulations (Fig 1).
Renal Function
The renal function findings are described in Table 3. As per inclusion criteria, the iGFR
was 90 mL/min/1.73 m2 in all patients. The mean (SD) value for iGFR was 118.1 (18.1) mL/
min/1.73 m2 (2 patients had high iGFR values of 147 and 161 mL/min/1.73 m2, respectively).
iGFR values are shown in Fig 2. Age-appropriate equations did not accurately estimate GFR in
this cohort of paediatric Fabry patients: the mean eGFR (SD) was 101.0 (16.6) mL/min/1.73
Table 2. GLA genotypes.
Nucleotide change No. of patients Codon change Associated phenotype, as reported in the literature
c.157_160del_AACC 1 p.Asn52FsX67a Novel
c.803T>C 1 p.Leu268Ser Classic phenotype [28]
c.679C>T 2 p.Arg227Xa Classic phenotype [29]
c.1025G>A 1 p.Arg342Gln Classic phenotype [30]
c.400delT 1 p.Tyr134Met_FsX31a Not specified [31]
c.644A>G 1 p.Asn215Serb Cardiac variant phenotype [32]
c.950T>C 1 p.Ile317Thr Classic phenotype [33] and cardiac variant phenotype [34]
c.802_805delTTAG 1 p.Leu268Xa Novelb
c.71G>A 3 p.Trp24Xa Novel
c.800T>G 1 p.Met267Arg Classic phenotype [35]
c.277G>A 1 p.Asp93Asn Classic phenotype [36]
c.982G>C 1 p.Gly328Arg Classic phenotype [37]
c.748C>T 1 p.Gln250Xa Classic phenotype[38]
c.1042G>C 3 p.Ala348Pro Classic phenotype [35]
c.613C>A 1 p.Pro205Thr Classic phenotype [39]
c.101A>G 1 p.Asn34Ser Classic phenotype [32]
c.874G>A 4 p.Ala292Thr Not specified [40]
c.647A>G 2 p.Tyr216Cys Classic phenotype [41]
c.1095delT 1 p.Tyr365fsXa Classic phenotype [42]
c.1117G>C 1 p.Gly373Arg Novel
c.658C>T 1 p.Arg220Xa Classic phenotype [43]
c.1235_6delCT 1 p.Thr412fsc Classic phenotype [44–46]
aSignifies truncating (nonsense) mutation.
bThis mutation could be identical to c.803delTAGT, previously described by Shabbeer et al. [33]
cSignifies frameshift mutation that extends protein sequence beyond natural stop codon.
doi:10.1371/journal.pone.0124987.t002
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m2. The Bland–Altman plot (Fig 3) shows the uncertainty for the eGFRBedside Schwartz equation
(n = 30). The bias (mean value of eGFR −measured GFR [mGFR]) was −18.0 ± 20.77 mL/min/
1.73 m2 and the interquartile range for the difference between eGFR and mGFR values was
Fig 1. Skin GL-3 scores in treatment-naive male paediatric patients with Fabry disease.Data missing for deep vessel endothelial cells (n = 2), deep
vessel smooth muscle cells (n = 17), and perineurium (n = 3); cell types not present in biopsy. GL-3 = globotriaosylceramide.
doi:10.1371/journal.pone.0124987.g001
Table 3. Renal function.a
Parameter Patients (N = 31)
iGFR, mL/min/1.73 m2
Mean (SD) 118.1 (18.1)
Range 90.4–161.0
eGFR, mL/min/1.73 m2
Mean (SD) 101.0 (16.6)
Range 71.0–151.0
Protein/creatinine ratio, mg/g creatinineb
Median 92.7
Range 4.8–168.8
Albumin/creatinine ratio, mg/g creatinineb
Median 10
Range 4.0–27.0
aRenal function data reported for the overall group. Renal function data for each of the treatment groups
will be reported once the study has been completed (in the context of the outcomes of the study).
bTo convert protein/creatinine ratio and albumin/creatinine ratio in mg/g to mg/mmol, divide by 8.84.
eGFR = GFR estimated from serum creatinine levels; GFR = glomerular filtration rate; iGFR = GFR
measured by plasma disappearance of iohexol; SD = standard deviation.
doi:10.1371/journal.pone.0124987.t003
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24.9 mL/min/1.73 m2. Percentages of the eGFR results within 30%, 20%, and 10% of the mGFR
results (a measure of accuracy) were 86.7%, 56.7%, and 16.7%, respectively.
As per inclusion criteria, urinary excretion of total protein and albumin was within the nor-
mal range in all patients. The median albumin/creatinine ratio was 10 mg/g. There were no ab-
normal results for beta-2-microglobulin, and all samples assayed were below the detectable
range (< 0.3 mg/dL creatinine) for retinol-binding protein.
Kidney Biopsy Findings
Optional kidney biopsies were performed in 6 patients aged between 13 and 17 years. No focal/
global glomerulosclerosis was observed in any of the 6 kidney biopsies. Fig 4 is an example of
the kidney biopsy images. One of the biopsies showed a glomerulus with cystic appearance and
dilated Bowman's capsule, with a few capillary loops with adhesions to the Bowman's capsule,
raising suspicion of being atubular. This glomerulus was excluded from the EM quantitative
studies.
The presence of GL-3 inclusions with characteristic electron-dense lamellar appearance of
myelin figures and zebra bodies was confirmed in these various cell types (Fig 4A and Fig 4B).
GL-3 accumulation was found by EM in glomerular endothelial cells, mesangial cells, podo-
cytes, and parietal epithelial cells in all 6 patients. All podocytes showed prominent accumula-
tion of GL-3 inclusions, distinctly more abundant than in any other kidney cells. The size of
the inclusions was variable, but in general, podocyte inclusions appeared to be larger than
those of other cells. There was segmental effacement of foot processes over the glomerular cap-
illary loops in all patients. In addition, GL-3 inclusions were observed in peritubular capillary
endothelium, interstitial cells, non-capillary endothelial cells, vascular smooth muscle cells,
and distal tubules/collecting duct cells (not quantitated).
EM revealed arteriopathy in all 6 biopsies (Fig 4C and Fig 4D), whereas LM showed mild
Fabry arteriopathy only in 2 of 6 biopsies. The arteriopathy was characterized by focal
Fig 2. Levels of glomerular filtration rate measured by plasma disappearance of iohexol (iGFR) in treatment-naive male paediatric patients with
Fabry disease. The red dashed line indicates the iGFR inclusion criterion for the study (90 mL/min/1.73 m2). iGFR = glomerular filtration rate as measured by
plasma disappearance of iohexol.
doi:10.1371/journal.pone.0124987.g002
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replacement of arterial/arteriolar smooth muscle cells by waxy, hyaline-like material. One glo-
merulus showed segmental mesangiolysis and microaneurysm formation on EM, but no other
features suggestive of a thrombotic microangiopathic process or any additional glomerulopa-
thy other than Fabry nephropathy.
Fig 3. Bland–Altman plot showing the uncertainty for the eGFR Bedside Schwartz equation.GFR = glomerular filtration rate; eGFR = GFR estimated
from serum creatinine levels; mGFR =measured GFR; SD = standard deviation.
doi:10.1371/journal.pone.0124987.g003
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Brain Morphology
Optional brain MRI scans were carried out on 21 of 31 patients: 19 were aged> 10 years and 2
were aged 6 years but did not require the use of an inhaled general anaesthetic. One patient was
found to have a white matter lesion (volume 178 mm3) on T2/FLAIR MRI. As the presence of
a white matter lesion> 2 mm was an exclusion criterion, this patient was wrongly included.
However, following an ad hoc review conducted by the Data Monitoring Committee a
Fig 4. Kidney biopsy images from amale patient with Fabry disease. (A) EM of a glomerulus. Arrows show GL-3 inclusions in podocytes (P), endothelial
cells (E), mesangial cells (M), and parietal epithelial cells (PEC). (B) EM of a distal tubule (DT) with GL-3 inclusions (arrows) accumulated in its epithelial
cells, in contrast to the adjacent proximal tubule (PT) with no obvious GL-3 inclusion. (C) EM close-up of the square shown in (D), displaying early Fabry
arteriopathy (asterisk) focally replacing smooth muscle cells (SMC) of an arteriolar wall. Arrows show GL-3 inclusions in adjacent smooth muscle cells. (D)
Methylene blue/Azure II (Richardson’s) stained semi-thin section of an arteriole. Note that the arteriopathy shown in (C) with higher magnification EM is not
easily identifiable by LM (square). Arrows show GL-3 inclusions in endothelial cells and smooth muscle cells of the artery. BC = Bowman's capsule;
DT = distal tubule; E = endothelial cells; EM = electron microscopy; FB = fibroblast; GL-3 = globotriaosylceramide; LM = light microscopy; M = mesangial
cells; P = podocytes; PEC = parietal epithelial cells; PT = proximal tubule; PTC = peritubular capillary; SMC = smooth muscle cells. EMmeasurements of GL-
3 deposition in glomerular cell types are shown in Table 4 [16]. Unbiased morphometric EM estimates of GL-3 in the three glomerular cell types including Vv
(Inc/PC), Vv(Inc/Endo), and Vv(Inc/Mes) [16,27], as well as podocyte foot process width and percentage glomerular capillary endothelial fenestration
[16,26,27] are tabulated in Table 4.
doi:10.1371/journal.pone.0124987.g004
Table 4. Kidney biopsy findings by electronmicroscopy.
Case Age (years) Vv(Inc/PC) Vv(Inc/Endo) Vv(Inc/Mes) %EF FPW (nm) Arteriopathy (yes/no)
1 13 0.25 0.13 0.04 44 558 Yes
2 17 0.30 0.09 0.06 61 593 Yes
3 15 0.31 0.17 0.03 56 615 Yes
4 15 0.29 0.12 0.05 52 626 Yes
5 15 0.27 0.12 0.05 57 744 Yes
6 17 0.31 0.15 0.06 56 671 Yes
Mean ± SD 15 ± 1.5 0.29 ± 0.02 0.13 ± 0.03 0.05 ± 0.01 54 ± 6 635 ± 65 Yes
Normal reference values in controls: FPW, 430 ± 61 nm; % EF, 61 ± 9 [16].
%EF = percentage glomerular capillary endothelial fenestration; FPW = foot process width; GL-3 = globotriaosylceramide; SD = standard deviation; Vv
(Inc/Endo) = fractional volume of endothelial cells occupied by GL-3 inclusions; Vv(Inc/Mes) = fractional volume of mesangial cells occupied by GL-3
inclusions; Vv(Inc/PC) = fractional volume of podocytes occupied by GL-3 inclusions.
doi:10.1371/journal.pone.0124987.t004
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posteriori (once the patient had been in the study for a substantial period), it was accepted that
the patient could continue the study.
Cardiac Abnormalities
As per inclusion criteria, cardiac morphology and function, assessed by echocardiography and
ECG, were unremarkable. All patients had a LV ejection fraction> 60%, relative wall
thickness< 0.45, and LV mass index< 50 g/m2.7.
Hearing Abnormalities
Audiology examinations and audiometry (hearing) tests were normal for 25 of 31 (81%) pa-
tients. Four patients had tinnitus and six patients had a degree of hearing loss (Table 1) at the
median age of 11.8 years (range 5–17 years). The type of hearing loss was conductive (n = 2),
sensorineural (n = 2), or of mixed type (n = 2). Three of these six patients had hearing loss that
was considered clinically significant. One patient had moderately severe unilateral sensorineu-
ral hearing loss, one had mild bilateral conductive hearing loss, and the third patient had mod-
erate unilateral conductive hearing loss.
Gastrointestinal Symptoms
The most frequent GI symptoms reported in this paediatric cohort were abdominal pain
(n = 20; median age 13 years; range 5–18 years), diarrhoea (n = 10; median age 13.5 years;
range 5–18 years), and nausea (n = 9; median age 13 years; range 6–17 years) (Table 1). These
were mostly mild to moderate in severity, although 4 (13%) patients experienced severe ab-
dominal pain. One of these patients had been the subject of a separate, independent report, due
to the unusually severe GI manifestations [47].
Angiokeratoma
Angiokeratomas were present in 15 patients. These were most commonly located on the poste-
rior trunk (n = 6), umbilicus (n = 6), and genitalia (n = 5). The median age of patients with
angiokeratoma was 14 years (range 10–17 years).
Quality of Life
QoL was diminished and fatigue commonly reported in this paediatric patient cohort, as dem-
onstrated by the average score of 68.8 out of 100 on the PedsQL Generic Core Scales and the
PedsQL Multidimensional Fatigue Scale questionnaires. Using a visual analogue scale, the
mean (SD) pain score was 13.9 (20.9) out of 100 in response to the question ‘How do you feel
now?’, and 39.4 (36.0) out of 100 in response to the question ‘What was your worst pain this
week?’.
For the question ‘How do you feel now?’, there was no linear relationship between age and
pain score (p = 0.89), but for the question ‘What was your worst pain this week?’ the relation-
ship reached statistical significance (p< 0.0001).
Discussion
This paper reports early disease status in a cohort of 31 treatment-naive young males with
Fabry disease without severe symptoms. Because they were enrolled in a clinical trial, the pa-
tients described in this analysis had extensive clinical and biochemical data available at base-
line. This provided a unique opportunity to comprehensively characterize the early
manifestations of disease in male children and adolescent patients prior to the development of
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clinically apparent renal disease. Currently, such information is scarce in the literature, but is
of great importance for the community responsible for caring and treating patients with Fabry
disease. An important clinical implication that can be drawn from our study is that, although
accurate measurement of GFR and assessment of proteinuria/albuminuria are useful, cellular
and tissue damage in the kidneys, in addition to extensive renal GL-3 accumulation, can be
present prior to clinically apparent renal dysfunction.
As expected, mean GL-3 levels in plasma and urine were elevated, and all patients had ele-
vated plasma lyso-GL-3 levels. The combined observations of complete enzyme deficiency,
mutations described in the literature as associated with classical presentation (except for the
patient with the p.Asn215Ser mutation)[28,35,41], and elevated plasma lyso-GL-3 suggest that
these patients are likely to develop severe complications of Fabry disease in adulthood if not
treated [48,49]. These data suggest that lyso-GL-3 has high diagnostic sensitivity in male paedi-
atric patients with a classical presentation of Fabry disease.
This is the largest cohort of children with Fabry disease in which GFR was measured in a
systematic, prospective, centralized manner [22]. As per the inclusion criteria, all patients in
this study had normal values for iGFR ( 90 mL/min/1.73 m2). Age-appropriate equations
were used to calculate eGFR. However, mGFR, considered the gold standard, was not predicted
accurately by these equations. This corresponds with earlier findings showing wide variations
from mGFR in the normal range in paediatric patients [18].
The data presented here might be indicative of disease progression at a relatively early age.
Kidney biopsies, in all 6 young patients who underwent the optional biopsy, in addition to GL-
3 accumulation in all cell types, showed evidence of injury to podocytes (i.e. foot process wid-
ening) and Fabry arteriopathy, despite the fact that in all patients the GFR and albuminuria
were within the normal range and no severe Fabry symptoms were reported. However, it is
noteworthy that despite being within the clinically accepted normal range, the median albu-
min/creatinine ratio (10 mg/g) was higher compared with reference values reported in healthy
adolescents [50,51]. This emphasizes the importance of follow-up and monitoring of albumin/
creatinine ratio at least annually in children with Fabry disease.
Similar to our findings, previous studies employing renal biopsies of children and adoles-
cents with Fabry disease also revealed significant GL-3 accumulation. This was characterized
by lamellar electron-dense material (myelin figures and zebra bodies) in various kidney cell
types, including podocytes, endothelial cells, mesangial cells, parietal cells, distal tubular cells,
interstitial, and vascular smooth muscle cells, in all untreated patients despite minimal or no al-
buminuria, and normal GFR [12,15]. A recent biopsy study of renal pathology in a cohort of 14
paediatric Fabry patients (median age 12 years) also revealed lamellar GL-3 inclusions in all
the glomerular cell types of patients, including a 4-year-old boy [16]. GL-3 accumulation was
most prominent in podocytes, and for the first time, age-dependent progressive accumulation
of GL-3 within podocytes was demonstrated [16]. The narrow age range in the patients who
had kidney biopsies in the current study resulted in only subtle variations in podocyte GL-3
density measurements.
Our findings of the EM quantitative analysis were similar to those already reported for male
Fabry patients of the same age (data not shown) [27], indicating that the selection criteria for
the FIELD study did not appear to select for a cohort with milder renal involvement. Similar to
previously reported observations [12,15,16,52], segmental foot process effacement— a mani-
festation of podocyte injury— was observed in all biopsies. When compared with normal con-
trol biopsies from living kidney donors [16], the average foot process width in the 6 patients in
whom biopsies were performed was significantly greater than in controls. This confirms the
previous observation that podocyte injury is occurring in young patients even before clinically
significant albuminuria or proteinuria manifests. Another important finding was the
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documentation of evidence of Fabry arteriopathy, indicating that Fabry-specific vascular le-
sions occur relatively early in the course of the disease. Fabry arteriopathy has been reported in
4 of 9 young patients aged 18 years by Tøndel et al. [15]. In the current study, LM detected
Fabry arteriopathy in only 2 of 6 biopsies. EM examination, however, confirmed these lesions
in the 2 patients, and revealed arteriopathy in another 4 patients, highlighting the importance
of EM examination in detection of early vascular lesions. We also observed 2 previously unde-
scribed glomerular lesions in 2 different biopsies, i.e. prominent segmental mesangiolysis with-
out any other evidence of thrombotic microangiopathy, and a glomerulus with cystic
appearance which raised suspicion of being atubular. Whether these lesions are of clinical sig-
nificance or are related to Fabry disease is not known.
In this cohort of paediatric patients without severe symptoms, significant GL-3 accumula-
tion was already present within multiple cell types in skin biopsies. The levels of GL-3 accumu-
lation in skin capillary endothelial cells in this cohort are comparable with pre-treatment levels
reported in adult patients [21,53,54]. A high proportion of these adults were shown to have
moderate (grade 2) deposition of GL-3. In the only other study that has reported pre-treatment
GL-3 levels in the skin capillary cells of paediatric patients, moderate or severe GL-3 deposits
were reported in superficial dermal endothelial cells of 12 of 14 boys, including the 3 youngest
patients, who were aged< 10 years when they started treatment with agalsidase beta [17]. In-
terestingly, the 4 patients with the lowest plasma lyso-GL-3 levels in the current cohort all had
zero scores for GL-3 accumulation in superficial skin capillary endothelial cells (data not
shown).
In the present cohort, pain levels, angiokeratoma, GI symptoms, brain morphology, cardiac
morphology and function, and hearing status were similar to those reported in previous studies
of untreated young patients [7,9,15,17,55]. However, it should be noted that the study excluded
patients with overt or known cardiac or central nervous system Fabry pathology. A recent
study of agalsidase beta in 10 children and adolescents with Fabry disease reported no clinical
Fabry manifestations in the heart, kidney, or brain before treatment was initiated, citing pain
as the major symptom in childhood Fabry disease. No skin or renal biopsies were carried out in
that study [55]. An open-label study of agalsidase beta in a paediatric cohort [17] also found no
clinically significant cardiac symptoms relating to Fabry disease before treatment was initiated,
although GI symptoms (postprandial pain, nausea, or vomiting) were present in the majority
of patients. In 2003, a survey of 35 paediatric patients reported the clinical characteristics of the
disease in childhood. The principal symptoms identified included acroparaesthesia, GI symp-
toms, headache, tinnitus, and fatigue. Renal involvement (proteinuria) was reported in 13% of
male patients [7]. Cardiac complications of Fabry disease may become apparent in childhood
as subtle changes with slow but detectable progression over time [56].
In terms of QoL, the treatment-naive male children and adolescents with Fabry disease
without severe symptoms described in our analysis had similar scores on the multidimensional
fatigue scale and the generic core scales, as previously reported for children with underlying
chronic disorders such as juvenile rheumatoid arthritis, cancer, and asthma [57].
The optimal time to initiate ERT remains controversial, although there is consensus that
treatment should be initiated before irreversible organ damage has occurred. Two ERT prepa-
rations are commercially available for treatment of patients with Fabry disease: agalsidase beta
(Fabrazyme) and agalsidase alfa (Replagal; Shire Human Genetic Therapies, Cambridge, MA,
USA; not available in the United States). Studies in adult patients have shown that agalsidase
beta treatment clears GL-3 accumulation in renal capillary endothelium. Continued reduction
in podocyte GL-3 has also been observed in some adult patients with sustained agalsidase beta
treatment [58], and ERT may slow the progressive decline in renal function [58–60]. Agalsidase
beta at 1.0 mg/kg has been shown to slow progression to the composite clinical outcome of
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renal, cardiac, and cerebrovascular complications and death compared with placebo in adult
patients with advanced disease [61].
In children and adolescents with Fabry disease, effective reduction or clearing of GL-3 accu-
mulation in skin [17] and renal tissue [12] was observed, and improvements in pain, GI symp-
toms, and energy levels have been reported [17,55]. Importantly, a recent study in young
patients (median age 16.5 years) showed that 5 years of ERT with either agalsidase alfa or agal-
sidase beta completely cleared GL-3 from mesangial and glomerular endothelial cells [12].
Clearance of GL-3 from podocytes was found to be dependent on the cumulative agalsidase
dose, and pronounced podocyte GL-3 clearance was associated with an improvement of micro-
albuminuria and podocyte foot-process effacement. GFR was normal and stable throughout
that study [12].
Our study has limitations. First, tissue samples from the kidney biopsies had low numbers
of glomeruli (LM: 2–8 per sample; EM: 2–3 per sample); the number of glomeruli assessed by
LM was lower than the number of glomeruli scored in studies using LM and the scoring system
of the International Study Group of Fabry Nephropathy [12,14]. The lower number of glomer-
uli potentially limits the strength of the observations. However, in our study, optional kidney
biopsies were conducted for 6 of the 31 enrolled patients, providing a good sample size in this
paediatric population. Secondly, no age-matched controls were included in this study, prevent-
ing direct comparison of the findings in this paediatric cohort with renal structure and function
in children without Fabry disease.
In conclusion, these observations in untreated male children and adolescents with Fabry
disease show that significant signs of GL-3 accumulation, as well as cellular and vascular injury,
are present in kidney biopsies in young patients without severe Fabry symptoms. For example,
GL-3 accumulation was evident in multiple types of kidney cells, and podocyte foot process
widening (indicative of podocyte injury) and Fabry arteriopathy were present in all biopsies de-
spite normal kidney function and the absence of microalbuminuria/proteinuria. These obser-
vations add to the limited number of studies that have described the clinical manifestations
and renal histopathology of Fabry disease in childhood and adolescence. Our findings highlight
the need for careful and thorough clinical evaluation of all patients and for regular follow-up to
monitor for early clinically significant organ involvement, such as early renal events. Kidney bi-
opsy is useful in children diagnosed with Fabry disease to assess the level of organ involvement
and to assist with treatment decisions.
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